Oregon Psilocybin Rules ‘May Have a Negative Impact on Lower Income Individuals’
The State acknowledges proposed psilocybin services rules will incur costs that “could ultimately be passed onto clients.”
The State acknowledges proposed psilocybin services rules will incur costs that “could ultimately be passed onto clients.”
This week in psychedelic business news: TripSitter expands; Enveric files a major patent; and Psychedelic Water raises its profile.
Interested in participating in a psychedelic study? Here’s an in-depth walk through guide so you can take actionable steps to make it happen.
A Doctor Explains Ibogaine: A Psychedelic Being Used to Heal…
Here’s why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
The Director of Research for Unlimited Sciences takes a deep dive into microdosing research to explore its effects, which may be placebo.
MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psychedelic-news/industry/
All Psychedelic Stock investors should take the time to listen to the conference calls of the companies they are investing in. That is doubly important for year-end calls, as often information is divulged on the direction of the company. If you are invested in MNMD or MMED stock, you need to listen to this call.
Follow us on Twitter:
The Psychedelic Investor: @psycInvestor
James: @Psy_Invest
Maria: @psy_holy
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Meet Kevin O’Leary, Rober Barrow, Daniel Carcillo and other psychedelic leaders @ the Benzinga Psychedelics Capital Conference.on April 19 @ Fontainebleau Hotel, Miami!
https://www.eventbrite.com/e/benzinga-psychedelics-capital-conference-spring-2022-tickets-238697028237?discount=PSYCHSPOTLIGHT15&fbclid=IwAR3tJFhoVfVWZvAyQuWSLEo3kJSmaq8VGnQQPz04NMhG3g7rHtSmRSAUq64
COUPON CODE: PSYCHSPOTLIGHT15
Interested in going to Malta for Plant Medicine Week April 5th-8th? Get discounted tickets here: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC
In this MindMed 2021 conference and earnings call, we gained important insights into the company’s many projects. These include: Project Lucy, which attempts to treat Anxiety using LSD; Project Angie, attempting to treat pain with LSD; Project Layla, attempting to treat addiction with 18-MC, and much more.
The company gives some updates on the science of psychedelics, as well as their hiring strategy and financial updates. MindMed is a company working on treating mental health conditions with psychedelics. They are a leading player in the shroom boom, and they aim to commercialize psychedelics as medicines.
Some of the questions MindMed is trying to answer are:
Can Psychedelics treat Mental Health conditions?
Can Psychedelics treat depression?
Can Psychedelics treat anxiety?
Can Psychedelics treat ADHD?
Can Psychedelics help with Autism?
Can Psychedelics help treat pain?
#MindMed #MNMD #MindMedStocks
Introducing the Benzinga Psychedelics Capital Conference on April 19 in Miami Beach,
This week in psychedelic business news: Filament Health scores 2nd psilocybin patent; a new psychedelics company emerges as one crumbles.
NeonMind finds that its proprietary psilocybin has the ability to target visceral fat, effectively reducing weight gain in obese subjects.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.